HCW Biologics Inc. is a preclinical stage biopharmaceutical company. It focused on discovering and developing novel immunotherapies. HCW Biologics Inc. is based in MIRAMAR, Fla.
Revenue (Most Recent Fiscal Year) | $2.84M |
Net Income (Most Recent Fiscal Year) | $-24.99M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 10.50 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.72 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -697.50% |
Net Margin (Trailing 12 Months) | -697.53% |
Return on Equity (Trailing 12 Months) | -146.76% |
Return on Assets (Trailing 12 Months) | -81.74% |
Current Ratio (Most Recent Fiscal Quarter) | 0.46 |
Quick Ratio (Most Recent Fiscal Quarter) | 0.46 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.95 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.23 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | -- |
Diluted Earnings per Share (Trailing 12 Months) | $-0.76 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 37.82M |
Free Float | 18.95M |
Market Capitalization | $41.23M |
Average Volume (Last 20 Days) | 0.03M |
Beta (Past 60 Months) | 1.04 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 49.90% |
Percentage Held By Institutions (Latest 13F Reports) | 2.96% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |